Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Eduard Fresenius

Fresenius Medical Care AG & Co. KGaA

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Avalon GloboCare Corp.

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical, Inc.

Bosch Service Solutions is an international provider of technology-based services, offering integrated service solutions in the automotive, logistics, healthcare, and communications technology industries.

Bosch Service Solutions

Fresenius Medical Care è il più importante gruppo al mondo nella produzione di dispositivi medici e nella gestione globale di servizi per il trattamento dell’insufficienza renale. Il Gruppo che opera in 150 paesi nel mondo con un totale di oltre 120.659 dipendenti, gestisce una rete di 4.000 cliniche con oltre 348.703 pazienti in trattamento dialitico (più di 6 volte il numero complessivo dei pazienti in dialisi in Italia).

In Italia, Fresenius Medical Care, è presente a Palazzo Pignano (CR) dove occupa circa 700 addetti tra Produzione e attività Commerciali e a Napoli dove viene effettuato il coordinamento delle attività dei centri dialisi gestiti da NephroCare S.p.A.

NephroCare S.p.A. è presente in 8 regioni Italiane con un’importante rete di centri dialisi accreditati (55), in particolare in Lombardia gestisce la Nefrologia e Dialisi dell’Ospedale Bolognini di Seriate (BG).

NephroCare S.p.A. segue in Italia oltre 2.800 pazienti in dialisi cronica, con uno staff di circa 600 addetti tra medici, personale infermieristico, ausiliario ed amministrativo.
Sempre nel comprensorio di Palazzo Pignano è presente inoltre un Polo Tecnologico Europeo di eccellenza con circa 50 collaboratori che sviluppano software innovativi in uso nei centri dialisi in tutto il mondo.

Fresenius Medical Care Italia

VIENI A TROVARCI! 

Il 62° Congresso Nazionale della Società Italiana di Nefrologia si terrà a Rimini dal 6 al 9 ottobre 2021.
Maggiori informazioni sono disponibili al link: https://lnkd.in/g94Mfa-5

Fresenius Medical Care parteciperà al Congresso Nazionale con uno spazio espositivo.

Raggiungici al nostro stand nell’area espositiva del Congresso e scopri i nuovi dializzatori FX CorAL!
Per saperne di più visita il sito: www.fx-coral.it

#62CongressoSIN #Nefrologia #Rimini #SocietàItalianaNefrologia #MembraneInsights

Metric
Company Name	Fresenius Medical Care AG & Co. KGaA	Avalon GloboCare Corp.	Avanos Medical, Inc.	Bosch Service Solutions
Symbol	FME	AVCO	AVNS
MSH ID	COM:FRESENIUSMEDICALCARE	COM:AVALON-GLOBOCARE	COM:AVANOS	COM:BOSCHSERVICESOLUTIONS
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Real Estate	Healthcare	Commercial & Professional Services
Industry	Medical - Care Facilities	Real Estate - Services	Medical - Devices	Technology Services
Country	DE	US	US	DE
Stage		Post-IPO
Employee Count	117.13K	5	3.77K
Website	freseniusmedicalcare.com	avalon-globocare.com	avanos.com	boschservicesolutions.com
LinkedIn	fresenius-medical-care-italia-spa
Founders

Metric
Market Cap	11.22B	5.26M	890.08M
Enterprise Value
Monthly Web Traffic		88
Web Traffic Growth		-0.85
Valuation
Raised Capital		20M

Metric
Revenue	20.55B	673.30M
Revenue (LTM)
Revenue (NTM)
Gross Profit	5.20B	382.70M
EBITDA	3.63B	98.50M
Operating Income	1.58B	52.40M
Net Income	527.06M	-61.80M
EPS	1.80	-1.33
Diluted EPS	1.80	-1.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.25	0.57
Operating Profit Margin	0.08	0.07
EBITDA Margin	0.18	0.15
Net Profit Margin	0.03	0.02
Return on Equity	0.04	0.01
Return on Assets	0.02	0.01
Return on Capital Employed	0.06	0.03

COM:FRESENIUSMEDICALCARE

Fresenius Medical Care

Last Close

42.25

25/11 09:24

Market Cap

10.62B

Beta: -

Volume Today

26.51K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	19.14	-15.55
P/B Ratio	0.75	0.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.63	1.66
EV Multiple	0.95	13.78

Metric
Days Sales Outstanding	69.66	70.67
Days Payables Outstanding	21.21	56.73
Days Inventory Outstanding	56.09	205.17
Operating Cycle	132.45	275.64
Cash Conversion Cycle	112.72	205.02
Asset Turnover	0.62	0.42

Metric
Operating Cash Flow	2.78B	32.40M
Free Cash Flow	2.05B	14.60M
Cash Flow to Debt	0.34	0.33
Operating Cash Flow/Sales	0.16	0.09
Free Cash Flow Yield	0.16	0.04

Metric
Cash & Equivalents	1.48B	87.70M
Accounts Receivable	-160.38M	39M
Inventory	2.30B	163.20M
Goodwill	15.47B	796.10M
Debt to Capitalization	0.47	0.15
Debt to Assets	0.36	0.18
Current Ratio	1.37	3.07
Quick Ratio	1.14	1.49

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.02	0.02
R&D to Revenue	0.01	0.04
SG&A to Revenue